3BBLACKBIOBSE3B BlackBio Dx LtdLowNeutral
Announced Wed, 28 May · 16:55 IST

Appointment of Secretarial Auditor

Management Changes View source PDF

3BBLACKBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

The board, at its meeting on May 28, 2025, approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, with an unqualified auditor opinion from Baheti & Co. Standalone FY25 revenue from operations rose to Rs. 9,052.97 lakhs from Rs. 7,072.45 lakhs in FY24 (~28% growth), while profit after tax jumped to Rs. 4,755.95 lakhs from Rs. 3,421.35 lakhs (~39% growth), pushing standalone EPS to Rs. 55.51 (vs Rs. 39.93). The board recommended a final dividend of 40% (Rs. 4 per share on Rs. 10 face value), subject to shareholder approval at the upcoming AGM. The Diagnostic Kits segment remains the larger revenue contributor compared to Agrochemicals. Additionally, Mr. Praveen Kumar Rai (P.K. Rai & Associates) was appointed as Secretarial Auditor for five years (FY26–FY30), and M/s Ali Jain & Sharma as Internal Auditor for FY26.

Likely market impact

Strong FY25 earnings growth and a healthy 40% dividend payout are positive for shareholders. The auditor appointments are routine governance items and signal continued compliance, with no negative signals for the stock.